Compare State Street SPDR Bloomberg High Yield Bond ETF (JNK) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
State Street SPDR Bloomberg High Yield Bond ETF vs Viatris Inc — how do they compare? State Street SPDR Bloomberg High Yield Bond ETF trades at $92.72 (market cap $5.86B), while Viatris Inc trades at $17.64 (market cap $20.03B). The key difference: Viatris Inc is far larger — about 3.4× State Street SPDR Bloomberg High Yield Bond ETF's market cap, and Viatris Inc pays a 2.75% dividend while State Street SPDR Bloomberg High Yield Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold State Street SPDR Bloomberg High Yield Bond ETF for 61 Days and Viatris Inc for 57 Days on average.
| JNK | VTRS | |
|---|---|---|
Market Cap | $5.86B | $20.03B |
Volume | 7,780,002 | 14,109,977 |
Sector | Fixed Income | Health |
52-Week High | $98.02 | $18.27 |
52-Week Low | $92.30 | $9.74 |
Typical Hold Time | 61 Days | 57 Days |
Enterprise Value | — | $32.15B |
Dividend Yield | — | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JNK (SPDR Bloomberg High Yield Bond ETF) trades at $92.81 with minimal daily movement (+0.05%). Technical indicators show a bearish trend with moving averages signaling sell pressure, though oscillators are neutral. The ETF maintains consistent dividend payments of $0.53 per share. Recent news highlights institutional interest with Envestnet Asset Management increasing its stake by 23.3% during the latest quarter.
The outlook for JNK is challenged by rising bond yields and macroeconomic uncertainty. While consistent dividends provide income appeal, the bearish technical setup and high-yield bond sensitivity to interest rate hikes present near-term risks. Institutional accumulation suggests long-term confidence, but investors should monitor credit market conditions closely.
Viatris (VTRS) trades at $17.64, up 0.86% on the day, with a bullish technical signal from moving averages and oversold RSI levels. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS of $0.69 exceeding expectations. Revenue for 2025 was $14.3 billion, though net income was negative. Analyst consensus is a 'Buy' with a $22.17 price target, representing 26% upside. Recent news highlights include a new drug approval in Japan and recognition as a top employer.
The outlook for VTRS is cautiously optimistic, supported by earnings beats and a positive analyst stance, but tempered by negative profit margins and high debt. Key opportunities include operational cash flow strength and pipeline progress, while risks involve sustained profitability challenges and competitive pressures in the generics market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About State Street SPDR Bloomberg High Yield Bond ETF
JNK is a major ETF tracking the Bloomberg High Yield Very Liquid Index. It provides exposure to U.S. dollar-denominated junk bonds with above-average liquidity, featuring 2026 top holdings like EchoStar, Cloud Software Group, and Carnival Corp.
Read more on JNK →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
